CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cuorips Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cuorips Inc
Phone: +81 362310043p:+81 362310043 CHUO-KU, TKY  103-0023  Japan Ticker: 48944894
Business Summary
Cuorips Inc is a Japan-based company mainly engaged in the development and commercialization of regenerative medical products and contract development and manufacturing organization (CDMO) business. The main product of the Company is human iPS cell-derived cardiomyocyte sheets. The Company provides regenerative medical products for the heart and other areas through in-house research, joint research with universities and other research institutions and major pharmaceutical companies. The Company operates CDMO business using CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Representative Director TakayukiKusanagi 8/1/2020 8/1/2020
Chief Technology Officer, Director YoshikiSawa
Vice President, Director ManabuInoue 1/1/2022 12/1/2020
Independent Director TetsuyaOhira 6/1/2021 6/1/2021
Independent Director TadashiSamejima 6/1/2022 6/1/2022

General Information
Number of Employees: 46 (As of 3/31/2023)
Outstanding Shares: 7,952,409 (As of 3/31/2024)
Shareholders: 31
Stock Exchange: TYO


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024